view preliminary programme
Friday, 27th June 2025
14:00 - 18:00
Registration
18:00 - 19:00
OPENING LECTURE: Chair: Karam Kostner and Martin Clodi
BALLROOM A&B
18:00 – 18:30
Time is of the essence: never mind future drugs, use what you have available to fullest extent and lower cardiovascular risk aggressively. - Peter Toth
18:30 – 19:00
What will change the LL landscape in the next 5 years - Maciej Banach
19:00
WELCOME RECEPTION
Saturday, 28th June 2025
07:30 - 17:00
Registration
08:30 - 10:00
PLENARY SESSION 1: LDL - Chairs: Karam Kostner and Derek Connolly
BALLROOM A&B
-----
08:30 – 09:00
LDL lowering in 2025: Optimal approach – Dereck Connolly
09:00 – 09:30
Gene Therapies: Lifetime cure for CVD – Christof Fellmann
09:30 - 10:00
How to implement LDL Guidelines: lessons from the FH paradigm - Gerald Watts
10:00 - 10:30
Sponsored Symposium: ARROWHEAD
BALLROOM A&B
Advances in the Diagnosis and Care of Severe Hypertriglyceridaemia and Chylomicronaemia Syndromes
Ioanna Gouni-Berthold (Chair) and Gerald Watts
10:30 - 11:00
Coffee Break, Exhibition
11:00 - 12:30
Parallel Sessions:
Workshop 1
Familial Hypercholesterolemia: joint session with the Austrian Atherosclerosis Society
Chairs: Gerald Watts and Hans Dieplinger
BALLROOM A&B
------
Workshop 2
Imaging Atherosclerosis and risk prediction
Chairs: Warrick Bishop and Walter Speidl
SALON SCHUBERT
------
11:00 - 11:30
FH: Genetics, Epidemiology: Steve Humphries
Can Cardiac CT guide lipid management? Warrick Bishop
------
11:30 - 12:00
Lessons from the Norwegian FH registry: Martin Borgsrud
Risk Scores and CV risk prediction algorithms: Walter Speidl
------
12:00 - 12:20
Newborn Screening: Caroline Bachmeier
Polygenic Risk Scores: Florian Kroenenberg
------
12:20 - 12:30
Austrian FH registry - update
Azin Kheirkhah
12:30 - 13:30
PLENARY SESSION 2: Lp(a)
Chair: Florian Kronenberg and Gerhard Kostner
BALLROOM A&B
------
12:30 – 12:40
Introductory remarks: Gerhard Kostner
------
12:40-13:10
Epidemiology, Genetics, Measurement: Florian Kronenberg
------
13:10 – 13:30
How to treat elevated Lp(a): Karam Kostner
13:30 - 14:30
Lunch Break / Exhibition
14:30 - 15:00
Sponsored Symposium: NOVARTIS
Lp(a) in daily clinical practice
Florian Kronenberg and Yvonne Winhofer
BALLROOM A&B
15:00 – 16:30
Parallel Sessions
Workshop 3
Diets and Nutraceuticals
Chairs: Maciej Banach and Karam Kostner
SALON SCHUBERT
------
Workshop 4
Proteomic markers, remnants and HDL:
Chairs: Caroline Bachmeier and Stanislav Oravec
BALLROOM A&B
------
15:00 – 15:30
Nutraceuticals to lower LDL and TG – Maciej Banach
The role of proteomic Markers in cardiovascular Risk Assessment – Winfried März
------
15:30 – 16:30
Short Oral Presentations
Valery Bochkov, Katharina Sophia Mair, Matilda Makungu, Olga Oskolkova, Jacqueline Ryan, Michela Saltori, Kamila Szeliga, Małgorzata Waluś-Miarka, Asmaa Bayyoudtamimi
-----
15:30 - 16:00
Comprehensive update on remnant lipoproteins and HDL: Peter Toth
16:00 – 16:30
Lipoprotein profiles identified by Lipoprint System in individuals with dyslipoproteinemia: Stanislav Oravec
16:30 - 17:00
Coffee Break, Exhibition
17:00 – 18:30
PLENARY SESSION 3: TG, parallel session for chylomicronemia syndromes,
Chairs: Gerald Watts and Peter Toth
BALLROOM A&B
------
17:00 – 17:45
Defining features and pathophysiology of Chylomicronemia syndromes: Gerald Watts
17:45 – 18:30
State of the art management of chylomicronemia syndromes – Peter Toth
19:30
NETWORKING DINNER
Sunday, 29th June 2025
07:30 - 15:00
Registration
08:30 – 10:00
PLENARY SESSION 4: What Clinicians must know about lipids in 2025
Chair: Dereck Connolly and Ionna Gouni-Berthold
BALLROOM A&B
------
08:30 – 08:45
FH: Steve Humphries
08:45 – 09:00
LDL: Karam Kostner
09:00 – 09:15
Lp(a): Florian Kronenberg
09:15 – 09:30
Risk Assessment: Warrick Bishop
09:30 – 09:45
Diabetic Dyslipidemia: Martin Clodi
09:45 – 10:00
TG: Peter Toth
10:00 - 10:30
Coffee Break, Exhibition
10:30 – 11:30
Sponsored Symposium: Amarin
Lipids as therapeutics – cardiovascular risk reduction with Icosapent-Ethyl
Chair: Walter Speidl
BALLROOM A&B
10:30 - 10:45
Omega-3 fatty acids and cardiovascular risk reduction – what do we know? Walter Speidl
10:45 – 11:00
Mechanisms of cardioprotection with high-dose EPA - Thomas Stulnig
11:00 - 13:00
Parallel Sessions:
Workshop 5
Diabetic Dyslipidemia; Joint Session with the Austrian Diabetes Society
Chairs: Natalie Koh and Peter Fasching
BALLROOM A&B
------
Workshop 6
Inflammation
Chairs: Winfried März and Christoph Binder
SALON SCHUBERT
------
11:00 – 11:30
Diabetic Dyslipidemia: Beyond LDL – Atherogenic Lipoproteins in Focus: Gersina Rega-Kaun
Role of Inflammation in Atherosclerosis: Christoph Binder
------
11:30 – 12:00
Effects of GLP-1 Receptor Agonists and SGL T2 Inhibitors on Lipid Metabolism: Bernhard Ludvik
Inflammatory Biomarkers: lessons from Luric: Winfried März
------
12:00 – 12:30
Lipoprotein(a) in Diabetes: A Neglected Cardiovascular Risk Factor? Natalie Koh
Focus on residual risk by targeting inflammation – who should we treat? Irene Lang
------
12:30 – 13:00
Targeting Triglycerides in Diabetes: Do We Need a Paradigm Shift? Thomas Stulnig
13:00 - 14:00
Lunch Break / Exhibition
14:00 - 15:30
PLENARY SESSION 5: Various
Chairs: Peter Toth and Kurt Derfler
BALLROOM A&B
------
14:00 – 14:20
SiRNA therapies: Challenges and opportunities: Derek Connolly
14:20 – 14:40
CV risk in Women: Elena Osto
14:40 – 15:00
Management of dyslipidemia in Pregnancy: Maciej Banach
15:00 - 15:15
Management of dyslipidemia in children: Kurt Widhalm
15:15
CLOSING REMARKS - Karam Kostner